Since a weaker glucose uptake ability is one of the major clinical features of T2DM, the inhibition of EPB41L4A‐AS1 expression seems to be a potentially effective strategy for drug development in T2DM treatment. The gene discussed is EPB41L4A; the disease is type 2 diabetes mellitus.